Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-CAR039 in Relapsed/Refractory B-NHL
NCT04655677Phase 1Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2020
- Primary completion
- Feb 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of prizloncabtagene autoleucel in B-cell non-Hodgkin lymphoma, sponsored by Peking Union Medical College Hospital. Primary endpoint: Incidence and severity of adverse events at 24 months. Started Oct 2020; status: completed.
02
Drugs
prizloncabtagene autoleucel
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04655677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04655677.